The axial spondyloarthritis market is undergoing rapid change as physicians increasingly recognize both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-AxSpA) populations. TNF-alpha inhibitors (AbbVie’s Humira, Amgen’s Enbrel, UCB’s Cimzia, and Janssen’s Simponi and Remicade) are the standard of care in AS patients who do not respond to conventional therapies such as NSAIDs. In March 2019, Cimzia became the first and only FDA-approved therapy for nr-AxSpA, and this approval may affect how physicians treat this subpopulation, which has been managed similarly to AS patients in the past. Two biosimilars of Remicade are also marketed in the United States. In 2016, Novartis’s IL-17 inhibitor Cosentyx became the first non-TNF biologic to be approved for AS and the first drug to bring a new mechanism of action to this indication in over a decade. This primary-market-research-based report explores current physician prescribing practices in both AS and nr-AxSpA patients, examining the use of biologics and conventional therapies in both indications. It also discusses factors that drive physicians’ use of key brands as well as anticipated changes in use in the coming year.

Questions Answered:

  •  At which line of therapy is Cosentyx used?
  • How long do physicians wait to prescribe a biologic to their AS patients?
  • What is the brand-level patient share of key biologics in AS and nr-AxSpA?
  • What are the key drivers for physicians to prescribe biologics to their AS patients?

Content Highlights:

Geographies: United States.

Primary research: Survey of approximately 100 U.S. rheumatologists.

Key drugs covered: Humira, Enbrel, Cimzia, Simponi, Remicade / biosimilars, Cosentyx.

Key insights provided: Factors influencing disease management and treatment decisions; drivers and constraints of treatment selection; physician-reported treatment practices and brand-level patient shares; rationale for changes in treatment approach; physician insight on persistency and compliance; physician-reported recent / anticipated changes in brand usage or treatment approach.

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Axial Spondyloarthritis - Current Treatment - Detailed, Expanded Analysis (US)
    • Current Treatment: Physician Insights Axial Spondyloarthritis US October 2019

Author(s): Qinghui Yu, PhD

Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases.

Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science industries. Qinghui Yu holds a Ph.D. in Neuroscience from Columbia University.


Related Reports

Axial Spondyloarthritis - Landscape & Forecast - Disease Landscape & Forecast

Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) marke...

View Details

Axial Spondyloarthritis | Disease Landscape and Forecast | G7 | 2020

Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blo...

View Details

Axial Spondyloarthritis - Access & Reimbursement - Detailed, Expanded Analysis: Axial Spondyloarthritis (ankylosing Spondylitis And Nonradiographic Axial Spondyloarthritis) - US

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s...

View Details

Axial Spondyloarthritis - Unmet Need - Detailed, Expanded Analysis: Ankylosing Spondylitis (US & EU)

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimz...

View Details